Literature DB >> 32421857

Novel outbreak of acral lesions in times of COVID-19: a description of 74 cases from a tertiary university hospital in Spain.

A Saenz Aguirre1, F J De la Torre Gomar1, P Rosés-Gibert1, J Gimeno Castillo1, Z Martinez de Lagrán Alvarez de Arcaya1, R Gonzalez-Perez1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32421857      PMCID: PMC7276798          DOI: 10.1111/ced.14294

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   4.481


× No keyword cloud information.
Since the outbreak of the novel coronavirus disease 2019 (COVID‐19), reports concerning suspicious COVID‐19 skin manifestations have been progressively increasing. Morbilliform, varicelliform or urticarial rashes were described first. Later, acral erythematous or purpuric lesions were reported.– At the Araba University Hospital in Spain, which covers a population of 340 000 people, we designed a descriptive study of 74 patients. We recruited all patients presenting with suspicious acral manifestations for COVID‐19 from 7 to 22 April 2020. The average temperature during this period was 14 °C. Patients with changes in their pharmacological drugs during the previous month were excluded. Owing to the pandemic, data on most patients reached us via teledermatology. Age, sex, medical history, occupation and clinical characteristics were recorded for each patient. The results are shown in Table 1.
Table 1
Result, %
Lesion morphology
EP76.4
PM40.54
Both EP and PM16.21
Erosion10.8
Swelling16.21
Distribution
Hands8.1
Feet95.94
Both4.05
Laterality
Unilateral31.08
Bilateral68.91
Symmetry
Symmetrical51.35
Asymmetrical44.59
Unknown4.05
Symptoms
Pruritus32.4
Pain27
Asymptomatic48.6
Extracutaneous manifestations
Frequency29.6
Type
Respiratory50
General50
Latency period, days16.15
COVID‐19 symptoms
Symptoms present
Cough52.38
Fever33.33
Asthenia/myalgia28.57
Diarrhoea/nausea/vomiting19
Dyspnoea9.52
Anosmia/ageusia4.76
Of 74 patients, 42 (56.8%) were male. Mean age was 19.66 years (median 14.5 years, range 3–100 years). A small percentage (5.4%) were healthcare workers or had close contact with such workers, while 24.32% reported close contact with a person with confirmed or clinically diagnosed COVID‐19. Most patients had erythematous papules (76.4%), similar to chilblains (Fig. 1), while 40.54% had purpuric macules. Nearly all patients showed foot involvement (95.94%) and the hands were affected in 8.1%. Bilateral (68.91%) and symmetrical (51.35%) were the most usual distribution patterns. The dorsa of the toes/fingers was the main affected location (74.3% on toes and 100% on fingers).
Figure 1

Typical acral cutaneous findings suspicious for COVID‐19: erythematous chilblain‐like plaques with an asymmetrical distribution in the dorsum of toes.

Typical acral cutaneous findings suspicious for COVID‐19: erythematous chilblain‐like plaques with an asymmetrical distribution in the dorsum of toes. Extracutaneous symptoms were found in 21 patients (29.6%), of which 50% also had clinical respiratory symptoms (cough and dyspnoea). In 66.7% of the cases, cutaneous manifestations developed after extracutaneous symptoms with a mean latency of 16.15 days. Two patients developed pneumonia (2.70%), both preceding the cutaneous symptoms. In our area, COVID‐19 PCR, which has a sensitivity of about 70%, was performed on 17 516 people and 4649 were positive. Owing to the limited availability of resources only 11 patients in our study underwent PCR, and 1 had a positive result. Six patients underwent blood investigations (including autoimmunity), which did not show relevant alterations; this is in line with a previous report.. A skin biopsy was taken from a lesion on the toe of one patient who had a negative serology test for COVID‐19, and histological examination revealed a lymphocytic perivascular and perieccrine infiltrate. Neither vascular occlusion nor intravascular thrombi were seen. Direct immunofluorescence study was negative. These findings are compatible with those previously described., The aetiology of these lesions remains unclear. A microangiopathic and inflammatory process is thought to occur., – Alternatively, activation of complement, leading to inflammation and thrombi formation has been proposed. However, neither our case nor the others previously published have described thrombi. More recent articles, have proposed a delayed antigen–antibody immunological reaction, which could explain their development in asymptomatic and paucisymptomatic patients. Interestingly, we noticed an increase in the number of acral lesions 25 days after the start of lockdown. Conversely, last April we did not have similar lesions registered. Thus, we wonder whether some factors related to quarantine might have been involved, such as lack of sun exposure and consequent low levels of vitamin D. We hope this paper will encourage sturdier studies. If the results validate our findings, acral cutaneous manifestations will represent a useful clue to identify COVID‐19 in asymptomatic and paucisymptomatic patients.

Acknowledgement

We wish to thank the collaboration of all our colleagues in the Dermatology Department of the Araba University Hospital, as well as the pathologists (Dr Malo‐Díez and Dr Martínez‐Aracil). We also thank the primary care physicians, physicians from the emergency department, pediatricians and other specialists from our hospital and from the primary care centres in our area who collaborated and helped us to perform this study.
  6 in total

1.  Cutaneous manifestations in COVID-19: a first perspective.

Authors:  S Recalcati
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05       Impact factor: 6.166

2.  Chilblain-like lesions on feet and hands during the COVID-19 Pandemic.

Authors:  Nerea Landa; Marta Mendieta-Eckert; Pablo Fonda-Pascual; Teresa Aguirre
Journal:  Int J Dermatol       Date:  2020-04-24       Impact factor: 2.736

3.  Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings.

Authors:  Athanassios Kolivras; Florence Dehavay; Daphné Delplace; Francesco Feoli; Isabelle Meiers; Laurenzo Milone; Catherine Olemans; Ursula Sass; Anne Theunis; Curtis T Thompson; Laura Van De Borne; Bertrand Richert
Journal:  JAAD Case Rep       Date:  2020-04-18

4.  Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic.

Authors:  J López-Robles; I de la Hera; J Pardo-Sánchez; J Ruiz-Martínez; E Cutillas-Marco
Journal:  Clin Exp Dermatol       Date:  2020-08-07       Impact factor: 4.481

5.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.

Authors:  Cynthia Magro; J Justin Mulvey; David Berlin; Gerard Nuovo; Steven Salvatore; Joanna Harp; Amelia Baxter-Stoltzfus; Jeffrey Laurence
Journal:  Transl Res       Date:  2020-04-15       Impact factor: 7.012

6.  Acral cutaneous lesions in the time of COVID-19.

Authors:  S Recalcati; T Barbagallo; L A Frasin; F Prestinari; A Cogliardi; M C Provero; E Dainese; A Vanzati; F Fantini
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-27       Impact factor: 6.166

  6 in total
  16 in total

Review 1.  Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19).

Authors:  J M Carrascosa; V Morillas; I Bielsa; M Munera-Campos
Journal:  Actas Dermosifiliogr       Date:  2020-10-15

2.  Cutaneous manifestations of coronavirus disease 2019 in 458 confirmed cases: A systematic review.

Authors:  Rashmi Jindal; Payal Chauhan
Journal:  J Family Med Prim Care       Date:  2020-09-30

Review 3.  COVID-19-related skin manifestations: Update on therapy.

Authors:  Laura Atzori; Sebastiano Recalcati; Caterina Ferreli; Leonard J Hoenig; Franco Rongioletti
Journal:  Clin Dermatol       Date:  2020-12-14       Impact factor: 3.541

4.  A systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID-19) who developed virus or drug-related mucocutaneous manifestations.

Authors:  Niloufar Najar Nobari; Farnoosh Seirafianpour; Milad Dodangeh; Afsaneh Sadeghzadeh-Bazargan; Elham Behrangi; Samaneh Mozafarpoor; Azadeh Goodarzi
Journal:  Exp Dermatol       Date:  2021-05-24       Impact factor: 4.511

Review 5.  Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19).

Authors:  J M Carrascosa; V Morillas; I Bielsa; M Munera-Campos
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2020-08-31

Review 6.  Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2.

Authors:  Francesca Salamanna; Melania Maglio; Maria Paola Landini; Milena Fini
Journal:  Front Med (Lausanne)       Date:  2020-12-03

Review 7.  Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature.

Authors:  Gürkan Kaya; Aysin Kaya; Jean-Hilaire Saurat
Journal:  Dermatopathology (Basel)       Date:  2020-06-30

8.  Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.

Authors:  L Le Cleach; L Dousset; H Assier; S Fourati; S Barbarot; C Boulard; C Bourseau Quetier; L Cambon; C Cazanave; A Colin; E Kostrzewa; C Lesort; A Levy Roy; F Lombart; J Marco-Bonnet; J-B Monfort; M Samimi; M Tardieu; P Wolkenstein; E Sbidian; M Beylot-Barry
Journal:  Br J Dermatol       Date:  2020-08-09       Impact factor: 11.113

Review 9.  Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Related to the COVID-19 Pandemic in Health Care Workers.

Authors:  Stephanie L Mawhirt; David Frankel; Althea Marie Diaz
Journal:  Curr Allergy Asthma Rep       Date:  2020-10-12       Impact factor: 4.806

Review 10.  Six months into the pandemic. A review of skin manifestations in SARS-CoV-2 infection.

Authors:  Martina Burlando; Roberto Russo; Emanuele Cozzani; Aurora Parodi
Journal:  Dermatol Ther       Date:  2020-12-14       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.